|
PAT-DX1 GLP toxicology reports received
|
24 May 2023 at 9:35am
|
|
Notification regarding unquoted securities - PAB
|
11 May 2023 at 2:25pm
|
|
Appendix 4C - Quarterly - 31 March 2023
|
24 April 2023 at 10:35am
|
|
Notification of cessation of securities - PAB
|
18 April 2023 at 4:50pm
|
|
Two new deoxymab patents granted in the USA
|
17 April 2023 at 9:50am
|
|
Updated guidance for PAT-DX1 phase 1 clinical study
|
31 March 2023 at 9:30am
|
|
New PAT-DX3 data demonstrates synthetic lethality
|
14 March 2023 at 9:30am
|
|
Appendix 4D - Half Year Accounts - 31 December 2022
|
24 February 2023 at 6:40pm
|
|
Application for quotation of securities - PAB
|
16 February 2023 at 2:20pm
|
|
Change in substantial holding
|
15 February 2023 at 5:45pm
|
|
Change in substantial holding
|
3 February 2023 at 4:25pm
|
|
Change in substantial holding
|
3 February 2023 at 4:25pm
|
|
Appendix 4C - Quarterly - 31 December 2022
|
31 January 2023 at 9:45am
|
|
Patrys Receives R&D Tax Incentive Refund
|
30 January 2023 at 10:20am
|
|
Response to ASX Price Query
|
14 December 2022 at 3:40pm
|
|
Investor Webinar Presentation
|
24 November 2022 at 2:00pm
|
|
Final Director's Interest Notice
|
17 November 2022 at 9:55am
|
|
Initial Director's Interest Notice
|
17 November 2022 at 9:45am
|
|
Notification regarding unquoted securities - PAB
|
17 November 2022 at 9:45am
|
|
Results of Annual General Meeting
|
16 November 2022 at 3:59pm
|
|
Chairman's Address and CEO Presentation to 2022 AGM
|
16 November 2022 at 10:10am
|
|
Patrys Appoints Dr Charmaine Gittleson as Chairman
|
16 November 2022 at 9:15am
|
|
Appendix 4C - Quarterly - 30 September 2022
|
28 October 2022 at 9:50am
|
|
PAT DX3 Crosses Blood Brain Barrier in Healthy Animals
|
17 October 2022 at 9:10am
|
|
Notification of cessation of securities - PAB
|
14 October 2022 at 10:10am
|
|
Notice of Annual General Meeting/Proxy Form
|
13 October 2022 at 12:20pm
|
|
Final Director's Interest Notice
|
6 September 2022 at 9:45am
|
|
Investor presentation
|
1 September 2022 at 9:50am
|
|
Initial Director's Interest Notice
|
31 August 2022 at 10:00am
|
|
Appointment of Non-Executive Director
|
31 August 2022 at 9:59am
|
|
Appendix 4G and Corporate Governance Statement
|
30 August 2022 at 7:05pm
|
|
Appendix 4E and 2022 Annual Report
|
30 August 2022 at 7:05pm
|
|
PAT-DX1 From Engineering Run Meets all Specification Tests
|
30 August 2022 at 9:35am
|
|
New Research Grant For Deoxymabs in Metastatic Breast Cancer
|
26 August 2022 at 10:20am
|
|
PAT-DX1/Radiation Combination Improves Brain Cancer Survival
|
10 August 2022 at 10:00am
|
|
Retirement of Non-Executive Chair
|
8 August 2022 at 9:30am
|
|
Appendix 4C - Quarterly - 30 June 2022
|
28 July 2022 at 9:25am
|
|
Change in substantial holding
|
27 July 2022 at 12:25pm
|
|
PAT-DX1 Engineering Run Successfully Completed
|
4 July 2022 at 9:35am
|
|
New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
|
14 June 2022 at 9:20am
|
|
CBCF funding to support deoxymab brain cancer development
|
3 June 2022 at 2:30pm
|
|
Patrys CEO to present at Bioshares Biotech Summit
|
11 May 2022 at 10:20am
|
|
Appendix 4C - Quarterly - 31 March 2022
|
28 April 2022 at 10:25am
|
|
Patrys strengthens executive team on path to clinic
|
26 April 2022 at 9:25am
|
|
Section 708A Cleansing Statement
|
14 April 2022 at 5:20pm
|
|
Application for quotation of securities - PAB
|
14 April 2022 at 5:20pm
|
|
Stable Cell Line for Production of PAT-DX3 Established
|
28 February 2022 at 9:10am
|
|
Appendix 4D - Half Year Accounts - 31 December 2021
|
24 February 2022 at 5:50pm
|
|
Application for quotation of securities - PAB
|
8 February 2022 at 10:55am
|
|
Appendix 4C - Quarterly - 31 December 2021
|
31 January 2022 at 10:10am
|
Patrys